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doi:10.1016/j.jfma.2012.03.009Background/Purpose: Active efflux is known to play a major role in the resistance of many
bacteria to antibiotics. To evaluate the possibility of overcoming resistance by suppressing
the efflux, we determined the effect of reserpine, an efflux pump inhibitor.
Methods: Intracellular accumulations and the minimal inhibitory concentrations (MICs) of ci-
profloxacin in M. tuberculosis H37Rv and 16 clinical isolates were determined, compared,
and analyzed. Nine of the clinical isolates were resistant to isoniazid and rifampin
(multiple-drug resistant MDR). Five of these were resistant to ciprofloxacin.
Results: A reserpine-inhibited efflux systemwas identified in the H37Rv control and 10:1 (90.9%)
of ciprofloxacin-susceptible and 4:1 (80%) of ciprofloxacin-resistant clinical isolates. The MIC of
ciprofloxacin decreased in the presence of reserpine in 3/10 (30%) of the ciprofloxacin-Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan.
(W.-J. Syu).
ight ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
790 T.-S. Huang et al.susceptible and 2/4 (50%) of theMDR ciprofloxacin-resistant strains that expressed efflux pumps.
Two of the efflux-positive, ciprofloxacin-resistant strains in which the MIC of ciprofloxacin was
not decreased by reserpine were found to carry a D94A gyrA mutation. In contrast, two strains
with the D94G gyrA mutation were susceptible to ciprofloxacin in the presence of reserpine.
An efflux-negative strain, highly resistant to multiple antibiotics, was found to have a novel
G247S mutation that differs from known mutations in the QRDR region of the gyrA gene.
Conclusion: These findings indicate t hat reserpine can increase intracellular concentrations of
ciprofloxacin, but is unable to overcome other mechanisms of resistance in clinical isolates.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
There were an estimated 9.4 million new cases diagnosed
and 1.7 million people died from tuberculosis (TB) in 2009
in the world.1 Although chemotherapy is highly effective for
drug-susceptible strains in compliant patient populations,
the world-wide emergence of multidrug resistant strains
(MDR) to the first-line agents, isoniazid and rifampin, and
often to second line agents has made treatment much more
difficult. This drug resistance has resulted in increased use
of fluoroquinolones in combination with other second-line
agents to treat tuberculosis.
The Mycobacterium tuberculosis (M. tuberculosis) DNA
gyrase type II topoisomerase is the unique target for fluo-
roquinolones.2 Subunits A and B of the DNA gyrase are
encoded by genes gyrA and gyrB. Acquisition of fluo-
roquinolone resistance is mainly due to mutations in
specific quinolone resistance-determining regions (QRDRs)
of the genetic targets.3 We and others indicate that the
genetic changes cannot completely account for the resis-
tance of clinical isolates.4e6 This has led to a search for
additional mechanisms of fluoroquinolone resistance.
Several efflux proteins have been described in laboratory-
derived fluoroquinolone resistant mutants of M. tuber-
culosis.7e9 To our knowledge, only one study has reported the
presence of efflux pumps in clinical isolates of M. tubercu-
losis.10 A decrease in the MIC of fluoroquinolones was associ-
ated with the presence of efflux pump inhibitors. However, it
is not clear whether efflux pumps are important determinants
of resistance in clinical isolatesofM.tuberculosis. Thecurrent
studywas designed to obtain additional information about the
intracellularevents thatoccurwheneffluxpumpinhibitorsare
added. To accomplish this, we directlymeasured intracellular
ciprofloxacin concentrations before and after the treatment
with the efflux pump inhibitor reserpine and determined its
effect on the susceptibility to ciprofloxacin.
We found that most of our clinical isolates, including MDR
strains, possess a reserpine-responsive efflux pump and that
some, but not all, became more susceptible to ciprofloxacin
in the presence of reserpine. These findings are explained, in
part, by mutations at the D94A gyrA and other sites in DNA.
Methods
Antibiotics and chemicals
Ciprofloxacin (Bayer, Wuppertal, Germany) and reserpine
(Sigma-Aldrich Co., St. Louis, MO) were prepared according
to the manufacturers’ instructions.Bacterial strains
Clinical isolates of M. tuberculosis were obtained from
patients with active tuberculosis at the Kaohsiung Veterans
General Hospital located in southern Taiwan. Ciprofloxacin
susceptibility was determined by standard agar dilution
method as described previously.11 Resistance was defined
as an MIC of  2 mg/L. The antimicrobial susceptibility to
a panel of commonly used anti-tuberculosis drugs was
determined by standard laboratory methods.12 M. tuber-
culosis strain H37Rv (MIC to ciprofloxacin 0.5 mg/L) was
used for quality control.
All experiments were performed in a class II type B2
biosafety cabinet within a biosafety level III facility.
DNA sequencing
DNA was extracted with the Qiagen MinElute PCR purifica-
tion kit (Qiagen, Valencia, CA, USA) according to the
manufacturer’s instructions. DNA segments of gyrA and
gyrB were amplified by polymerase chain reaction (PCR)
with the forward and reverse primers described by Siddiqi
et al.13 The amplification was carried out with a GeneAmp
System 9600 thermocycler (Perkin-Elmer Corp., Foster City,
CA, USA) with the following parameters: 5 minutes at 94C
followed by 30 cycles of 60 seconds at 94C, 30 seconds at
58C for gyrA and 56.5C for gyrB, and 60 seconds at 72C
and terminated with a final extension step at 72C for
10 minutes. The PCR products were purified and sequenced
with an automated sequencer, ABI PRISM 310 Genetic
Analyzer (ABI, Applied Biosystems, Foster City, CA, USA).
The sequence data were compared with those previously
published.
Measurement of fluoroquinolone accumulation
A modified fluorometric method was adapted to accommo-
date the growth characteristics of mycobacteria.14 M.
tuberculosis colonies were suspended in 7H9 broth. The
mixture was vortexed and allowed to settle for 20 minutes.
The supernatant fluid was then transferred to a second tube.
After theprocesswas repeatedtwice, thecellswerediluted in
10mLof50mMsodiumphosphatebuffer (pH7.0)andadjusted
with a colorimeter (Vitek) to yield 10% transmittance. The
suspension contained approximately 108 CFU/mL.
The suspension was incubated at 37C in a water bath for
10 min. Ciprofloxacin was added at a final concentration of
10 mg/L. The suspension was then divided into two equal
portions. Reserpine was added at a final concentration of
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to the other. 1-mL samples were removed from each at 5, 8,
11, 15, and 20 minutes. The cells were immediately
centrifuged at 12,000 rpm in an Eppendorf microfuge
(model 5403) for 3 minutes at 4C. The pellets were washed
once with ice-cold sodium phosphate buffer (50 mM, pH 7)
and resuspended in 1 mL of 0.1 M glycine hydrochloride
(pH 3). The samples were left overnight at room tempera-
ture with agitation. They were then centrifuged again and
the supernatants were filtered through a 0.45 mm filter to
remove debris of lysed bacteria. The intracellular concen-
tration of ciprofloxacin was determined by a fluorescence
spectrophotometer atrst author ta would not go to the
trash can, ve told her so. As to credits, we should have an
open mind to share es not ha the excitation wavelengths of
275 nm and emission wavelengths of 440 nm.15 The pres-
ence of an efflux system was defined as a >30% increase in
the intracellular concentrations of ciprofloxacin over a 20-
minute period in the presence of reserpine compared to
paired untreated controls. Efflux positive strains exhibited
reproducible increases of 55 to 154%.
Statistical analysis
Statistical significance of differences between or among
groups was analyzed by the Kruskal-Wallis test. The Eta-
value was used as a measure of nonlinear correlation in the
crosstab in the SPSS version 12.0 software program.
Results
Effect of reserpine on intracellular concentrations
of ciprofloxacin
The study strains consisted of 16 clinical isolates of
M. tuberculosis. A laboratory strain of H37Rv served as
a quality control. Among the clinical isolates, 11 were
ciprofloxacin-susceptible and 5 were ciprofloxacin-
resistant. Nine were MDR strains (resistant to at leastFigure 1 The effect of reserpine on 16 clinical isolates of
M. tuberculosis. The shaded area represents the efflux positive
strains (intracellular ciprofloxacin accumulation increased in
the presence of reserpine); the hatched area represents the
strains whose MIC was reduced in the presence of reserpine.
Strains R2 and R3 have a D94A mutation in the gyrA gene;
strains R1 and R5 have a D94G mutation in the gyrA gene; strain
R4 has G247S mutation in the gyrA gene.isoniazid and rifampin). Four of these were susceptible to
ciprofloxacin and five were resistant (Fig. 1).
A reserpine-sensitive efflux system was observed in 10/
11 (90.9%) of the ciprofloxacin-susceptible strains and 4/5
(80%) of ciprofloxacin-resistant strains (Fig. 1). Strains S6
and R4 lacked a reserpine-sensitive efflux system. Strain S6
was susceptible to all antimicrobials tested. R4, an MDR
strain, was resistant to ciprofloxacin, ofloxacin, levo-
floxacin, and moxifloxacin. It was also resistant to para-
amino-salicylic acid (PAS) and borderline-susceptible to
kanamycin (MIC 6 mg/L). This strain was found to have
a novel G247S gyrA mutation that differs from known
mutations in the QRDR region of the gyrA.
Intracellular accumulation of ciprofloxacin in the
presence or absence of reserpine
All strains of M. tuberculosis rapidly accumulated cipro-
floxacin, reaching a steady-state within 3e5 minutes as
reported by other investigators.16 The intensity of fluores-
cence at 5 minutes in the 14 efflux-positive isolates is
shown in Fig. 2. There was a significant relationship
between the intracellular concentrations of ciprofloxacin
and susceptibility to the drug (p Z 0.011). The four non-
MDR ciprofloxacin susceptible strains with MICs of 0.25 to
0.5 mg/L exhibited significantly higher levels of fluores-
cence than all other strains. All eight MDR strains (Fig. 2)
and two non-MDR strains with MICs of 1 mg/L were found to
have relatively low levels of fluorescence. The non-MDR
strains tended to accumulate more ciprofloxacin than
MDR strains (p Z 0.02).
Effect of reserpine on the MIC of ciprofloxacin
Reserpine reduced the MIC of ciprofloxacin in 3/11 (27.2%)
reserpine-responsive ciprofloxacin-susceptible clinical
isolates (Fig. 1) and H37Rv. There was a 2-fold reduction in
the MIC of ciprofloxacin for strains S2 and H37Rv, 4-fold
reduction for strain S10, and >16-fold reduction for strain
S3. There was a greater than 3-fold reduction in the MIC of
ciprofloxacin for strains R1 and greater than 64-fold for
strain R5. Both strains carried a D94G gyrA mutation.
Lack of correlation between accumulation of
ciprofloxacin in the presence of reserpine among
ciprofloxacin-susceptible and resistant strains
In order to determine whether mechanisms other than
a reserpine-sensitive efflux might account for differences in
the intracellular accumulation of ciprofloxacin, we
compared the percent increase in ciprofloxacin fluores-
cence in the presence of 20 mg/L of reserpine to controls at
20 minutes incubation. The effect of reserpine on accu-
mulation of ciprofloxacin in ciprofloxacin-susceptible non-
MDR strains, ciprofloxacin-susceptible MDR strains, and
ciprofloxacin-resistant MDR strains is shown in Fig. 3. There
were no significant differences in the effect of reserpine on
accumulation of ciprofloxacin among the groups (p values
of 0.78 and 1.07, respectively). We examined the correla-
tions of MICs of ciprofloxacin with percent increase of
ciprofloxacin accumulation in the presence of reserpine as
Figure 2 Accumulation of ciprofloxacin in 14 clinical isolates of M. tuberculosis shown to have reserpine-sensitive efflux pumps.
Ciprofloxacin was added to the bacterial suspension and the intracellular concentration of ciprofloxacin was determined by
fluorescence spectrometry (see text). Each dot represents the mean of three measurements from an individual strain. The
coefficient of variation over the three measurements for each point averaged for all strains is 0.17. The corresponding MIC is shown
on the horizontal axis. A ciprofloxacin MIC of 2 mg/L is defined as resistant.
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this measure, there was a modest correlation between MICs
of ciprofloxacin and increase accumulation of ciprofloxacin
in the presence of reserpine in ciprofloxacin-susceptible
strains, with an Eta-value 0.571. There was no significant
difference between CIP-S non-MDR and CIP-S MDR groups
(p Z 0.085).Figure 3 The effect of reserpine on ciprofloxacin accumulation
and absence of 20 mg/L of reserpine, ciprofloxacin was added to th
within the bacteria at 20 minutes was determined by a fluorescenc
ciprofloxacin was calculated as the increased amount of ciprofloxac
absence of reserpine. The coefficient of variations over the three m
and 0.24 for the intensity of fluorescence measured at 20 minute
corresponding MIC in the absence of reserpine is shown in the horizo
“Resistant.” The strains in which the MIC of ciprofloxacin decrea
Reserpine reduced the MIC of S2 from 0.5 mg/L to 0.25 mg/L; S3: 0.
<2 mg/L; R5: 16 mg/L to <0.125 mg/L. The gyrA gene mutationsGene mutation
The gyrA and gyrB genes of all 16 clinical isolates and H37Rv
were amplified by PCR and examined by sequencing. None
had mutations in gyrB. There were no mutations in gyrA in
the ciprofloxacin-susceptible group. In contrast, all five
ciprofloxacin-resistant strains exhibited a gyrA mutation.in 14 efflux-positive strains of M. tuberculosis. In the presence
e bacterial suspension and the amount of ciprofloxacin retained
e spectrophotometer. The percent increase in accumulation of
in in the presence of reserpine in relative to the amount in the
easurements for each point, averaged for all strains, are 0.08
s in the absence and presence of reserpine, respectively. The
ntal axis, and the MIC of ciprofloxacin of 2 mg/L is defined as
sed in the presence of reserpine are shown in open circles.
5 mg/L to <0.06 mg/L; S10: 1 mg/L to 0.25 mg/L; R1: 4 mg/L to
are also labeled.
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had a D94G mutation in the QRDR region. Strain R4 had
a novel G247S mutation in gyrA.
All isolates tested, regardless of susceptibility to cipro-
floxacin, carried an S95T substitution in the gyrA gene. This
is consistent with the previously reported finding that S95T
is a marker for evolutionary genetics and does not correlate
with drug resistance.17Discussion
Antimicrobial drug resistance in M. tuberculosis can occur
by several independent mechanisms. These include muta-
tions at target genes or unidentified loci, modif
ication of the target(s), decreased permeability and efflux
pumps.18
Efflux pump-mediated antibiotic resistance has been
described in many bacterial pathogens.19 Drug efflux
transporters from all known families except the MATE
family (multidrug and toxic compound extrusion family) are
found in the sequenced genome of M. tuberculosis strain
H37Rv (http://www.membranetransport.org). Some have
been characterized and shown to be involved in fluo-
roquinolone resistance. They all belonged to the ATP-
binding cassette (ABC) superfamily (DrrABC, PstB, and Rv
2686c-Rv2687c-Rv2688c operon). These transporters are
sensitive to reserpine, an ATP-dependent efflux pump
inhibitor. Genes drrAB expressed in M. smegmatis confer
resistance to a broad range of clinically relevant antibi-
otics, including norfloxacin. The resistance phenotype is
reversed by treatment with efflux pump inhibitors
reserpine and verapamil.20 On the other hand, a laboratory-
generated M. smegmatis mutant with high-level transcrip-
tion and chromosomal amplification of the pstB gene
increases phosphate uptake. Disruption of pstB and thus the
phosphate-specific protein in M. smegmatis was correlated
with a decrease in ciprofloxacin efflux and resulted in an
increasing susceptibility to ciprofloxacin.15 The M. tuber-
culosis Rv2686c-Rv2687c-Rv2688c operon confers resistance
to ciprofloxacin (8 MIC) and, to a lesser extent, to nor-
floxacin (2 MIC) when over-expressed in M. smegmatis.
The levels of resistance decreased in the presence of efflux
pump inhibitors: reserpine, carbonyl cyanide m-chlor-
ophenylhydrazone (CCCP), and verapamil.9
Drug pumps belonging to the RND family and MATE family
and known to confer fluoroquinolone resistance are found
in numerous species of Gram-negative bacteria, other than
mycobacteria.19
It is generally accepted that increases in accumulation
of fluoroquinolones or reduction of the MIC in the presence
of reserpine can serve as surrogate markers for the pres-
ence of an active efflux system.21 Fluorescence spectros-
copy, employed in the current study, has been shown to be
a reliable method to determine the intracellular accumu-
lation of ciprofloxacin in the clinical isolates of M. tuber-
culosis.16 Reserpine increased the accumulation of
ciprofloxacin in 14 of 16 (87.5%) clinical isolates and H37Rv
regardless of their susceptibility to ciprofloxacin. These
findings are consistent with a recent report by Escribano
et al.10 It has been found that resistances to ofloxacin and
ciprofloxacin of clinical isolates of M. tuberculosis werereduced by the efflux pump inhibitors MC207.110. And addi-
tion of reserpine led to reduction of the MIC of 6/6 cipro-
floxacin resistant strains and 11/12 ciprofloxacin-susceptible
strains. A major difference from their findings is that our
addition of reserpine decreased the MIC of ciprofloxacin in
only 2/5 (40%) of ciprofloxacin-resistant strains and 3/11
(27.3%) of susceptible strains. It is not entirely clear why the
high rate of increase in accumulation of ciprofloxacin in the
presence of reserpine did not lead to a reduction of MICs to
ciprofloxacin for all clinical isolates. This difference could be
explained by strain selection (both sampling of small
numbers) and geographic differences in the relative abun-
dance of resistant strains. Our finding of a dissociation
between inhibition of efflux pumps and antimicrobial
susceptibility of clinical isolates ofM. tuberculosisare similar
to those reported for fluoroquinolone-resistant clinical
isolates of Streptococcus pneumoniae (45.4%)22 and Pseu-
domonas aeruginosa (37.8%).23
We found no significant differences in the percent
increase of intracellular concentrations of ciprofloxacin in
the presence of reserpine among ciprofloxacin-susceptible
non-MDR strains, ciprofloxacin-susceptible MDR strains, and
ciprofloxacin-resistant MDR strains. This raises the possi-
bility that another independent mechanism, unrelated to
efflux pump activity, might account for differences among
the strains in accumulation of ciprofloxacin. We are
currently exploring whether decreased permeability could
account for this phenomenon.
In summary, we found that most clinical isolates of M.
tuberculosis are able to accumulate ciprofloxacin and
express a reserpine-sensitive efflux pump. Reserpine
augments susceptibility to ciprofloxacin in some, but not
all, ciprofloxacin-susceptible strains. MDR strains were
found to be less susceptible to ciprofloxacin than non-
MDR strains and to accumulate lower intracellular
concentrations of the drug; this phenomenon is probably
due to the characteristics of MDR strains themselves
because fluoroquinolone-resistant MDR-TB was not
necessarily from a patient previously treated with fluo-
roquinolones.6 Addition of reserpine markedly increased
the susceptibility of ciprofloxacin-resistant strains
carrying the D94G gyrA mutation. However, reduction of
ciprofloxacin MICs in the presence of reserpine varied
independently of gyrA mutation. Several independent
mechanisms appear to be responsible for differences in
susceptibility to ciprofloxacin in MDR strains. In addition
to mutations in gyrA, other mechanisms such as
decreased uptake and variations in intracellular distri-
bution need to be explored.Acknowledgments
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